Fig. 5
CircPDE5A inhibits ESCC proliferation and metastasis in vitro and in vivo by encoding PDE5A-500aa. A–C The proliferative capacity of KYSE30 cells assessed by CCK8 (A), plate cloning (B), and EdU (C) assays following treatment with the vector, circPDE5A, circPDE5A-Mut, and PDE5A-500aa plasmids. Bar in (C) represents 50 μm. D Motility of KYSE30 cells determined by wound healing assay after treatment with the vector, circPDE5A, circPDE5A-Mut, and PDE5A-500aa plasmids. Bar represents 100 μm. E Migration and invasion ability of KYSE30 cells assessed by transwell assay after treatment with the vector, circPDE5A, circPDE5A-Mut, and PDE5A-500aa plasmids. Bar represents 1,000 μm. F WB analysis performed to evaluate the levels of EMT marker proteins in KYSE30 cells after treatment with the vector, circPDE5A, circPDE5A-Mut, and PDE5A-500aa plasmids. G Representative images of nude mouse xenograft tumors (n = 6) generated by subcutaneous injection of KYSE30 cells transfected with the vector, circPDE5A, circPDE5A-Mut, and PDE5A-500aa, respectively. H Volume growth curves of nude mouse xenograft tumors. Tumor volume was measured every 7 days after inoculation for 6 weeks (n = 6, unit: mm3). I Measurement of the weight of xenograft tumors in nude mice at the end of the experiment (n = 6, unit: mg). J Representative bioluminescent images of lung metastases formed by tail vein injection of KYSE30 cells transfected with the vector, circPDE5A, circPDE5A-Mut, and PDE5A-500aa, respectively (n = 6). K Schematic representation and HE staining of representative lung tissue from each group. Bar represents 2,000 μm. L Number of metastatic lung nodules in each group (n = 6). ***P < 0.005. ns, not significant